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Atomic force microscopy (AFM)
A B S T R A C T
HPMC capsules are made by a dipping process and a surface lubricant for the mould pins is an essential
processing aid for removing dried capsules shells. For the purpose of this study, the level was determined
by quantifying methyloleate (MO) a component found in the lubricant but not in the hypromellose
capsules. Here we investigated the inﬂuence of the lubricant, low (10.81 mg/capsule = 60 mg/kg MO),
medium (15.97 mg/capsule = 90 mg/kg MO) and high (23.23 mg/capsule = 127 mg/kg MO) content on
powder (binary mixture of salbutamol: lactose, 1:50 w/w) aerosolization properties was investigated.
Results indicated signiﬁcantly lower emitted dose from capsules with 60 mg/kg MO. Furthermore, the 90
and 127 mg/kg MO level of lubricant capsules produced almost double the Fine Particle Dose & Fine
Particle Fraction compared with the low level of lubricant. The data indicates that lubricant level within
capsules has an inﬂuence on deposition proﬁles and amount of drug remaining in capsule and inhaler
device after actuation. It is suggested lubricant levels greater than 60 mg/kg MO per capsule are required
to minimise powder retention within capsules and maximise deposition proﬁles. AFM (atomic force
microscopy) data suggest that internal surface roughness may be related with this phenomena.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Delivery of therapeutic agents via the pulmonary route has
gained increasing applications for lung diseases such as asthma
and COPD. Pulmonary delivery has many advantages including
delivery of medication directly to site of action, bypassing ﬁrst pass
metabolism in the liver (Geller, 2009; Labiris and Dolovich, 2003),
it is non-invasive and can achieve therapeutic outcome at lower
doses than administration via the oral route (Smith and Parry-
Billings, 2003).
Dry powder inhaler (DPI) are able to deliver low and high doses
within the range of 5–500 mg, do not require co-ordination
between actuation and inspiration as with pMDI (Kaialy et al.,
2012). They have been developed since the 1960’s for a range of
conditions such as asthma and COPD using short and long acting
beta agonists, anti-cholinergic agents and corticosteroids drugs in
order to facilitate drug administration to the lungs via the
inhalation route (Atkins, 2005). Today there are currently more
than twenty commercially available DPI, both active and passive
(Chan et al., 2014). New active DPI incorporate additional* Corresponding author. Fax: +44 0 151 231 2170
E-mail address: i.saleem@ljmu.ac.uk (I.Y. Saleem).
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0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article unmechanisms within the device to aid the ﬂuidization of the
powder from the device and reduce the reliance on the patient’s
inspiratory force. These mechanisms include vibration mesh which
oscillates upon the patient’s inhalation, others include release of
the powder formulation only when the patient has achieved the
correct inspiratory force (Chan et al., 2014). Passive DPI have unit
doses of drug in either blister packs or capsules, which contain the
drug and a carrier, e.g. lactose, and drug deposition relies on the
patient’s inspiratory force to de-aggregate the drug from the
carrier (Chan et al., 2014; Kaialy et al., 2012; Zhou and Morton,
2012).
The powder mass in the capsules allows ﬂexibility for the
administration of low and high dose drugs within the range of 5 to
500 mg. Examples of capsule based devices include the single unit
HandiHaler1 (Boehringer-Ingelheim) (Islam and Gladki, 2008),
TOBI1 PodhalerTM (tobramycin) and Colobreathe1 Turbospin1 for
delivery of large doses (Claus et al., 2014), Breezhaler1 (Novartis),
(Young et al., 2014) and novel multiple pre-metered unit-dose
Flowcaps1 (Hovione) that contains up to 20 capsules (Friebel and
Steckel, 2010). These devices are simple to use, cost-effective and
can administer low and high doses. In addition, the capsule based
devices improve patient compliance, as they can provide feedback
to the patient in the form of a rattling sound, indicating correctder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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deliver the correct dose (Behara et al., 2014; Smith et al., 2010).
Moreover, the patient can visually check the capsule to determine
if the dose has been administered (Smith et al., 2010).
Hypromellose (HPMC) is used to make inhalation grade
capsules (Quali-V1-I) for use in DPI, as it is unaffected by moisture
content changes (Jones, 2008). Hence, it does not become brittle
as it loses moisture, a common phenomenon with gelatin
capsules as patients do not store them as directed resulting in
broken capsules and poor performance in their DPI (Nagata, 2002;
Ogura et al., 1998; Renswouw et al., 2010). In addition, it has also
been shown that HPMC capsules are less inﬂuenced by tribo-
electriﬁcation which is common with gelatin capsules (Nakate
et al., 2005). Inhalation grade HPMC capsules are made from
different grades of raw material chosen for their puncturing
properties (Torrisi et al., 2013) and as a result have a slightly higher
moisture content; 4.5–6.5% compared to 4.0–6.0% in oral
pharmaceutical grade capsules. The HPMC Capsules are manufac-
tured by dipping stainless steel mould pins at room temperature
into a warm solution of hypromellose containing carrageenan as a
network former and potassium chloride as a network promoter
(Jones, 2004). The change in temperature causes the HPMC
solution to gel and form a ﬁlm on the surface of the mould pins. The
ﬁlms are dried by passing groups of pins through a series of drying
kilns in which large volumes of air at controlled temperature and
humidity is blown over them. As the ﬁlms dry they shrink on to the
pins. To remove them without damage it is essential for the mould
pins to be coated with a surface lubricant to act as a release aid.
Capsules cannot be manufactured without this lubricant (Jones,
2008). However, a search of the literature only shows one study
investigating the inﬂuence of the amount of mould lubricant on the
internal surfaces of capsules in relation to the aerosolization
properties of powders from a capsule based DPI (Saim and
Horhota, 2002). Furthermore, this study relates to gelatin capsules
and not HPMC.
The lubricant is a mixture of food and pharmaceutical grade
materials registered with regulatory authorities and the composi-
tion is proprietary for each capsule manufacturer. Hence for
quantitative analysis it is necessary to choose a component of
the lubricant which is not found in the HPMC capsules. In this
study we chose methyloleate (MO) as a marker for lubricant
content consisting of free fatty acids together with their esters.
A number of sample preparation methods have been proposed
in the literature to convert free fatty acids into their esters,
such as silylation (Woo and Kim, 1999) or reaction with
alkyl chloroformates (Gimeno-Adelantado et al., 2001) as well
as for transesteriﬁcation of the triglycerides (Mason and Waller,
1964).
The aim of this study was to investigate the aerosolization
properties of dry powder formulations composed of inhalation
grade lactose and micronized salbutamol, ﬁlled in to size
3HPMC inhalation grade capsules manufactured with 3 different
lubricant levels via an 8-pin inhaler device. Size 3HPMC
capsules was chosen because this is the size used in the
pharmaceutical industry for development of capsule-based DPI.
For example the last signiﬁcant developments in inhalation
capsule-based devices, Ultibro and Seebri Breezhaler, incorporate
their respective dry powder formulation into a size 3 capsule.
This size capsule (0.8 mg/mL) has a powder ﬁll weight of
225 mg. Furthermore, to the best of our knowledge, the capsule
inner surface lubricant content has not been determined by
GCMS or its distribution in HPMC capsules by AFM. Hence, we
describe a new technique with results obtained using these
methods in this study.2. Material and methods
2.1. Materials
8-pin monodose inhaler was provided by Plastiape S.p.a Italy.
Hypromellose (HPMC) inhalation grade capsules, size 3 (Quali-V1-
I) for this inhaler, manufactured using three different lubricant
levels (satisfactory physical quality capsules were made at each
level); low (10.81 mg/20 mg of blended powder within capsule =
60 mg/kg MO), medium (15.97 mg/20 mg of blended powder
within capsule = 90 mg/kg MO) and high (23.23 mg/20 mg of
blended powder within capsule = 127 mg/kg MO) were obtained
from Qualicaps1 Europe, S.A.U, Spain. Inhalation grade lactose
(Respitose) was supplied by DFE Pharma, The Netherlands.
Micronized salbutamol was obtained from Lusochimica, Spain.
Methanol and 1-heptane sulphonic acid sodium salt were
purchased from Sigma, UK. Methyloleate analytical standard,
hexane and chloroform were from Sigma–Aldrich (St. Louis USA).
1,2,3 Trichlorobenzene was purchased from Fluka and was used as
internal standard. Trimethylsulfonium hydroxide solution,
(TMSH), 0.25 M in methanol was used for GC derivatization.
2.2. Determination of methyl oleate (MO) in capsules by gas
chromatography mass spectrometry
Gas chromatography mass spectrometry, GCMS, is the tech-
nique most suitable for its qualitative and quantitative determi-
nation after derivatization and extraction into an organic solvent
(Driscoll et al., 2009; Sutherland, 2007; Zhanga et al., 2014).
Capsules inner lubricant content was evaluated by determining
MO which was taken as a marker of the lubricant content using
GCMS. Eleven HPMC capsules were weighted in a glass vial and
5 mL of Hexane: chloroform, 60:40 (v:v) extraction solvent
containing 10 mg/L of the internal standard was added. The vial
was sonicated for 1 h in an ultrasonic bath; then 100 mL of the
extract was transferred into a 2 mL vial for derivatization using
50 mL of TMSH. The MO was identiﬁed by MS (Mass spectrometry)
and was quantiﬁed using an internal calibration method with six
points in the 0.5–20 mg/kg concentration range. 1 mL of the
derivatized MO was injected in split less mode in the GCMS
instrument.
2.3. Preparation of inhalation grade lactose & powder mix
Inhalation grade lactose and powder mix were prepared
according to previously published method (Saleem et al., 2008)
with slight modiﬁcations. Inhalation grade lactose was fractionat-
ed by sieving with a sieve stack (250, 125, 90, 63, and 45 mm) using
vibration amplitude of 40 for 10 min and collected on a 90 mm
sieve to be used in all subsequent studies. Micronized salbutamol
sulphate and lactose were mixed in a ratio of 1:50 (w/w) via
geometric dilution to obtain a 2% binary blend. The formulations
were blended with a Turbula1 orbital mixer (Glen Mills, Clifton,
New Jersey) for 30 min at 46 rpm. The blend uniformity was
determined by randomly selecting ﬁve 20 mg samples, and
formulations were considered uniform when the coefﬁcient of
variation (% CV) was 6%. Samples were analyzed using high-
performance liquid chromatography (HPLC) method below
(Section 2.4). Once blend uniformity was achieved 20  1 mg of
blended powder was manually loaded into HPMC capsules
(size 3) with different lubricant levels (low, medium and high)
and stored in a humidity chamber (Sanyo Atmos Chamber) at
22 C and 40% RH for 2 weeks (Nine HPMC capsules were ﬁlled for
each lubricant level at weeks 1 and 2).
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For each lubricant level, three capsules (20  1 mg of powder
loaded into HPMC capsules (size 3)) corresponding to a dose of
408 mg were dispersed through a 8-pin DPI inhaler into a next
generation cascade impactor (NGI; MSP Corporation, Shoreview,
MN) at a ﬂow rate of 60 L min1 actuated for 4 s, with 15 mL of
mobile phase added to the pre-separator. This was repeated three
times (n = 3). Drug depositing in the capsule, inhaler, mouthpiece
adaptor, induction port, pre-separator and NGI stages were
collected by rinsing each component with mobile phase. This
was repeated at week 2 and the drug content was assessed via
HPLC method (Section 2.4).
The emitted dose (ED) was calculated as the total mass of drug
depositing in the mouthpiece, induction port, pre-separator, and
NGI stages. The ﬁne particle dose (FPD) was determined as the
mass of drug deposited in the NGI with aerodynamic diameters
4.46 mm. The percentage ﬁne particle fraction (% FPF) of each
dose was the ratio of the drug mass depositing in the
NGI (aerodynamic diameter 4.46 mm) over the emitted dose.
Mass median aerodynamic diameter (MMAD) was calculated
by subjecting the inertial impaction data to log-probability
analysis.
2.5. Chemical analysis
Capsules internal lubricant analysis were carried out by gas
chromatography coupled to mass spectrometry, GCMS, using a GC
7890 (Agilent Technologies, Palo Alto, CA, USA) and a 5975C
quadrupole mass spectrometer (Agilent Technologies, TX, USA). A
Supelcowax 10 (30 m  0.25 mm  0.25 mm ﬁlm thickness) fused
silica capillary column was used. The injection port temperature
was 240 C and the oven temperature program changed from 40 C
to 240 C at 10 C/min.
Salbutamol sulphate was analyzed by HPLC (Agilent Technolo-
gies) using a Kinetex C18 column (50  4.6 mm i.d. packed with
2.6 mm, phenomenex, UK). The mobile phase consisted of
methanol and 0.25% (w/v) 1-heptane sulphonic acid sodium salt
(45:55 v/v), the ﬂow rate was 1 mL/min, injection volume 10 mL,
temperature 25 C and wavelength was 200 nm. The retention timeFig. 1. Deposition of salbutamol sulphate remaining in capsules (A) and device (B) follo
(ANOVA/Tukey’s) Low (60 mg/kg MO) versus medium (90 mg/kg MO) & high (127 mg/kfor salbutamol sulphate was 3 min and the limits of detection and
quantiﬁcation were 0.60 and 1.12 mg/mL respectively.
2.6. Morphology of inner capsule surface
Atomic force microscopy, AFM, is a widely used technique for
micro- and nanoscale material characterization creating a three
dimensional image of a physical surface (Garcı’a and Pérez, 2002).
A commonly employed measurement approach is based on
tapping-mode AFM which involves a short and pulsed contact
between the tip of an oscillating micro-cantilever and the sample
surface. Vibrations of the cantilever tip are induced through dither
piezo oscillations from which heights and phases are monitored for
imaging purposes (García, 2010).
The AFM (atomic force microscopy) experiments were made
using a multimode Nanoscope III A (Bruker) in tapping mode in
order to access surface topography. It is equipped with three
scanners of 1, 1.5 and 150 m. Small pieces of 5  5 mm were cut and
placed onto the Nanoscope probe. The instrument standard sample
capsule probe was made of stainless steel but it was not suitable to
handle the curved shape of a capsule; so, a special home-made
support device was designed. Topographic measurements of the
inner capsules surface at a ﬁxed scanning angle equal to zero were
made using tapping mode (intermittent contact mode). The
cantilever/tip assembly was sinuously vibrated by a piezo device
mounted above it, and the oscillating tip slightly taped the surface
at the resonant frequency of the cantilever with constant
oscillating amplitude introduced in the vertical direction with a
feedback loop keeping the average normal force constant.
Measurements were made using a silicon probe (Veeco probe)
with a spring constant of 5 N/m and a resonance frequency of
150 kHz. All experiments were performed in air at ambient
conditions. In order to stabilize thermally the piezo driver, the
machine was turned on two hours before use. During each
measurement a 15 15 mm surface was covered using a FESP tip.
2.7. Statistical analysis
The data obtained were analyzed statistically by one-way
analysis of variance (ANOVA) with the Tukey’s comparison usingwing aerosolisation at 60 L min1 from a 8-pin inhaler (Mean  SD, n = 3) **P < 0.05
g MO) lubricant levels at weeks 1 and 2.
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signiﬁcance were considered when p < 0.05. All values are
expressed as the mean  standard deviation.
3. Results and discussion
3.1. In vitro aerosolization performance
3.1.1. Comparing capsules and device
Comparing HPMC capsules (Fig. 1A) the results clearly indicate
a signiﬁcantly larger salbutamol retention in the low lubricant
capsule (week 1: 84.01 49.23 mg, week 2: 80.76  31.25 mg)
compared to the medium (week 1: 17.70  9.34 mg, week 2:
14.37  2.20 mg) and high lubricant capsules (week 1:
24.91 13.79 mg, week 2: 38.36  17.89 mg) (p < 0.05, ANOVA/
Tukey’s). However, there was no signiﬁcant difference regarding
salbutamol retention between medium and high lubricant
capsules at week 1 and 2. A similar trend was observed with
drug deposition remaining in the 8-pin inhaler (Fig. 1B). It is
evident from the data that lubricant level within the capsule is
important, with data suggesting lubricant levels between 90 and
127 mg/kg MO per capsule result in signiﬁcantly lower drug
deposition within the capsule and inhaler device. The high
salbutamol retention in low lubricant capsules occurred, because
during the removal of the capsules from the mould pins there is a
high degree of adhesion that causes roughness, which can be seen
by the mountain and deep valleys, as shown by AFM (see
Section 3.2). Hence during inhalation the salbutamol particles
become entrapped or lodged within these peaks and crevices
(Saim and Horhota, 2002). However, this effect is reduced
signiﬁcantly as the level of lubricant increases to greater than
90 mg/kg MO lubricant per capsule. This results in a smooth inner
surface of the capsule with less mountain and valleys (see
Section 3.2) as there is less adhesion during the removal from
the moulding pins, and hence, reduction in contact betweenFig. 2. Emitted dose (mg) (A), Fine particle dose (mg) (B), Fine particle fraction (%) (C), MM
8-pin inhaler (Mean  SD, n = 3) **P < 0.05 (ANOVA/Tukey’s) Low (60 mg/kg MO) versusparticles and crevices (Ibrahim et al., 2000; Saim and Horhota,
2002).
3.1.2. Comparing emitted dose, ﬁne particle dose, ﬁne particle fraction
& MMAD
Fig. 2 shows the ED, FPD, FPF and MMAD of salbutamol
aerosolized from an 8-pin inhaler at 60 L/min. The ED is
signiﬁcantly lower for the low lubricant level capsules (week 1:
223.73  42.72 mg, week 2: 217.69  63.85 mg) compared to the
medium (week 1: 324.57  32.06 mg, week 2348.42  1.17 mg) and
high lubricant capsules (week 1: 335.65  33.70 mg, week 2:
309.35  37.67 mg) (p < 0.05, ANOVA/Tukey’s). These results were
repeated for ﬁne particle dose (mg) (Fig. 2B) and ﬁne particle
fraction (%) (Fig. 2C) where the values are almost twice that
obtained using low lubricant capsules (p < 0.05, ANOVA/Tukey’s).
This coincides with the high deposition of salbutamol remaining in
the low lubricant capsules (Fig. 1A) and the device (Fig. 1B).
Furthermore, the MMAD (mm) (Fig. 2D) is signiﬁcantly greater
from low lubricant capsules (week 1: 3.37  0.78 mm, week 2:
2.71 0.03 mm) compared to medium (week 1: 2.13  0.11 mm,
week 2: 1.78  0.57 mm) and high (week 1: 2.12  0.16 mm, week 2:
1.65  0.17 mm) (p < 0.05, ANOVA/Tukey’s). This also conﬁrms the
low FPD and FPF within the lungs, due to large particle size and
hence less drug depositing within the deep lungs.
3.2. AFM studies
Topographic plots from three capsule inner surfaces are
represented in Fig. 3. They were taken as examples of the twelve
capsules analyzed, which were selected at a low, medium and high
concentrations that were previously determined by GCMS (Driscoll
et al., 2009; Sutherland, 2007; Zhang et al., 2014).
As can be seen, the topographic images show a mountain and
deep valley distribution of the lubricant oil in the inner surface of
the capsules. Similar results have been obtained using gelatinAD (mm) (D) of salbutamol sulphate following aerosolisation at 60 L min1 from an
 medium (90 mg/kg MO) & high (127 mg/kg MO) lubricant levels at weeks 1 and 2.
Fig. 3. Topographical image of capsules inner surface containing (A) low (26 mg/kg MO), (B) medium (63 mg/kg MO) and (C) high (137 mg/kg MO) levels of methyloleate.
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the inner surface appeared to be more homogenous (i.e. reduced
mountain and deep valley distribution) (Fig. 3A and C).
Four parameters derived from these plots (roughness, depth,
particle height and grain height) (Fig. 4) were used to obtain better
knowledge regarding inner capsule lubricant distribution. The
average from three different points on each capsule surface was
used to plot the different parameters versus MO concentration. It is
apparent (Fig. 4a) when the MO concentration increases, the
roughness, represented by Ra, decreased, indicating thatFig. 4. Methyloleate concentration effect on (A) roughneshomogeneity of capsule surface is higher when it is covered more
completely with the lubricant.
Reproducibility of the capsule inner surface can be evaluated by
paying attention to two capsules groups containing three capsules
with similar MO concentration, approximately 59 and 104 mg/kg
respectively as indicated by the red circle in Fig. 4A. The
reproducibility of the Ra parameter increases when MO concen-
tration is higher. This seems to indicate that homogeneity of the
lubricant inner surface is also enhanced when its concentration is
higher.s, (B) Depth, (C) particle height and (D) grain height.
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decreased when MO concentration increased (Fig. 4B–D), which
conﬁrmed the surface decreased when MO concentration
increases. In fact this tendency is also apparent in Fig. 4A–D, in
which dispersion of the respective parameters through an average
straight line decreases when the inner lubricant concentration
increases.
4. Conclusion
The study clearly indicates that the lubricant level inside
capsules has an inﬂuence on deposition proﬁles, amount of drug
remaining in capsule and inhaler device after actuation. The results
obtained suggest lubricant levels greater than 10.81 mg per capsule
(60 mg/kg MO) are beneﬁcial in decreasing drug deposition from
capsules in an 8-pin inhaler device, while more than doubling the
ﬁne particle dose and fraction. It seems this effect is related to the
capsule internal surface roughness. Measurements with AFM
indicated that homogeneity of the internal capsule surface is
higher when the inner lubricant concentration increases.
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